|
Study of Combined RHUMAB VEGF and Capecitabine-based Chemoradiation for Patients with Locally Advanced Pancreatic Cancer Clinical Trials Resources presented on Clinical Trials Search is not meant to be a substitute for proven health advice, calls or treatment with a real medical. We aren't mDs. Always consult your doctor on Study of Combined RHUMAB VEGF and Capecitabine-based Chemoradiation for Patients with Locally Advanced Pancreatic Cancer conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. Study of Combined RHUMAB VEGF and Capecitabine-based Chemoradiation for Patients with Locally Advanced Pancreatic Cancer Clinical research trials and Study of Combined RHUMAB VEGF and Capecitabine-based Chemoradiation for Patients with Locally Advanced Pancreatic Cancer healthcare trials take place in a lot of of localities throughout the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically assess the effectiveness of new does drugs. The function of the studies / projects is to figure out specific human medical questions. Clinical trials are a popular means for doctors, government agencies, and private sector corporations to find cures for all varieties of conditions, like Study of Combined RHUMAB VEGF and Capecitabine-based Chemoradiation for Patients with Locally Advanced Pancreatic Cancer. Study of Combined RHUMAB VEGF and Capecitabine-based Chemoradiation for Patients with Locally Advanced Pancreatic Cancer Clinical Trials and other clinical trials allow volunteers to access health treatment options before they are available to the masses. Many times the subjects receive professional assistance for free, and every now and again they are compensated for their time. Sometimes there is a cost for a Study of Combined RHUMAB VEGF and Capecitabine-based Chemoradiation for Patients with Locally Advanced Pancreatic Cancer clinical trial. Human subjects often obtain the finest healthcare possible for their Study of Combined RHUMAB VEGF and Capecitabine-based Chemoradiation for Patients with Locally Advanced Pancreatic Cancer condition. Hazards are a reality, nevertheless, and might include additional or frequent dr. calls, health hazards (potentially life-jeopardizing), and/or the treatment being uneffective. Trials are federally regulated with stern guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "S" Clinical Trials Conditions > Study of Combined RHUMAB VEGF and Capecitabine-based Chemoradiation for Patients with Locally Advanced Pancreatic Cancer  Study of Combined RHUMAB VEGF and Capecitabine-based Chemoradiation for Patients with Locally Advanced Pancreatic Cancer
Study of Combined RHUMAB VEGF and Capecitabine-based Chemoradiation for Patients with Locally Advanced Pancreatic Cancer
For Condition: Pancreatic Cancer
Status: Recruiting
Sponsor(s): M.D. Anderson Cancer Center ,
Synopsis: The goal of this clinical research study is to find the highest safe dose of the drug Bevacizumab that can be given in combination with chemoradiation for the treatment of pancreatic cancer. The effect that this combination treatment has on the tumor will also be studied.
Details: This study administers 50.4 Gy of radiation for unresectable pancreatic cancer with concurrent capecitabine and an experimental drug, Bevacizumab. The drug is an antiangiogenic agent (kills tumor blood vessels) and has been shown in preclinical models to enhance the antitumor effect of radiation and chemotherapy.
Eligibility:
Study Type: Interventional, Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety Study
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: Inclusion: - Cytology or histologic proof of adenocarcinoma of the pancreatic head, body or tail prior to treatment. - Patients with nonmetastatic, unresectable, disease are eligible. - Patients with regional nodal disease are eligible. - Karnofsky performance status >/=70. - No upper age restriction. - Absolute granulocyte count >1,500 cells/mm3 and platelet count at least 100,000 cells/mm3. - Serum bilirubin less than 5mg/dl prior to the start of therapy with adequate biliary decompression. - Adequate bilateral renal function. - Serum creatinine <1.5 mg/dl. - Adequate liver function; Alanine aminotransferase (ALT)/aspartate aminotransferase (AST)
Total Enrollment: 48
Location and Contact Information:
University of Texas MDAnderson Cancer Center *Recruiting*
Houston, Texas, 77030
United States
Recruiting Christopher Crane 713-563-2340
Additional Information:
Study ID Numbers: ID02-146;
Study Start Date: September 2002
Record last reviewed: January 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00047710
Other Pancreatic Cancer Studies:
1. OSI-774 (Tarceva) Plus Gemcitabine in Patients with Locally Advanced, Unresectable or Metastatic Pancreatic Cancer.
2. Photodynamic Therapy in Treating Patients With Cancer of the Bile Duct, Gallbladder, or Pancreas
3. Monoclonal Antibody ABX-EGF in Treating Patients With Renal (Kidney), Prostate, Pancreatic, Non-Small Cell Lung, Colon or Rectal, Esophageal, or Gastroesophageal Junction Cancer
4. Aminocamptothecin in Treating Patients With Advanced Cancer of the Peritoneal Cavity
5. Diagnostic and Genetic Study to Identify Pancreatic Lesions in Patients With Von Hippel-Lindau Syndrome
Related Studies:
Other Pancreatic Cancer Clinical Trials
Other Texas Clinical Trials
Other Houston Clinical Trials
Study of Combined RHUMAB VEGF and Capecitabine-based Chemoradiation for Patients with Locally Advanced Pancreatic Cancer
|
|
|
|
|
|
|
|
